Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Redx Pharma to present clinical trial poster at Madrid oncology meeting as administration continues

Redx’s shares remain suspended on AIM as it continues to be under administration, although an exit is expected in the future after the firm struck a deal at the end of July to sell its Bruton’s tyrosine kinase programme for US$40mln
Cancer tests
The life sciences group entered administration in May when Liverpool Council called in a £2mln loan

Redx Pharma PLC (LON:REDX) has announced it will present a poster on their planned first-in-human clinical trial for its RXC004 colorectal cancer treatment at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid on September 9.

The positive news comes with Redx’s shares remaining suspended on AIM as it continues to be under administration, although an exit is expected in the future after the firm struck a deal at the end of July to sell its Bruton’s tyrosine kinase (BTK) inhibitor technology and drug development programme for US$40mln.

READ: Redx Pharma shares suspended as Liverpool City Council calls in loan

The life sciences group’s shares were suspended in May after it entered into administration when Liverpool Council called in a £2mln loan.

FRP Advisory, RedX’s administrator revealed on August 10 that it had contemplated a fund raise to pay off Liverpool Council.

As there was no precedent for the raising of funds on AIM by a company in administration, this required detailed analysis of the legal structuring and in-depth discussions with the biotech's brokers and advisers, FRP Advisory added.

In the event, FRP said, one large shareholder vetoed the plan and the administrator subsequently sold the BTK inhibitors business to US firm Loxo.

READ: Administrators of Redx Pharma mulled fund raise to pay off Liverpool Council

BTK was to be one of the second-generation of compounds with fewer side-effects than the market leader Imbruvica (often referred to as Ibrutinib).

The next steps out of administration are for FRP to be satisfied that Redx can continue as a going concern, following which control will be handed back to the directors who are expected at that point to apply for trading on AIM to resume again.

The process is expected to be take up to 12 weeks.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use